The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.

Additional Metadata
Keywords Allergic rhinitis, Allergic Rhinitis and Its Impact on Asthma, Development and Evaluation, Grading of Recommendations Assessment, guidelines, real-world evidence
Persistent URL dx.doi.org/10.1016/j.jaci.2019.06.049, hdl.handle.net/1765/120354
Journal Journal of Allergy and Clinical Immunology
Citation
Bousquet, J. (Jean), Schünemann, H.J, Togias, A. (Akdis), Bachert, C, Erhola, M. (Martina), Hellings, P.W, … Zuberbier, T. (2019). Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology. doi:10.1016/j.jaci.2019.06.049